Menu Back toRegister

DIA 2018 Global Annual Meeting


Registration fees

The prices below are industry pricing. Reduced pricing may be available for Nonprofit/Academia and Government, subject to eligibility verification. Click Register to get pricing appropriate for your work setting. Review the cancellation and transfer policy.

Early Bird:
List Price:
Member Price:



  • #20: Real World Evidence Studies to Evaluate the Safety and Effectiveness of Therapeutic Interventions – Is the Data Fit for Purpose and How Will You Know? $415
  • #21: The IDMP Challenge: Points to Consider for Pharmacovigilance Departments $415
  • #22: Protocol Co-Design with Patients and Advocates $415
  • #23: R&D QA Comprehensive Quality Strategy: An Approach to Managing Quality Risks Throughout the Drug Development Lifecycle $415
  • #24: Preparing for a US FDA Advisory Committee Meeting $415
  • #25: Precedent: A Driver of Regulatory Strategy $415
  • #26: Good Practices in Concentration-QTc Modeling $415
  • #27: The Evolving Role of Payers in Drug Development: Pricing, Pharmacoeconomics, and Health Technology Assessment $415
  • #28: Preparing Documents for Disclosure and Public Sharing $415
  • #29: Leadership: How to Organize and Lead People in a Work Group $415
  • #30: Implementing a Risk-Based Monitoring Solution: Understanding the Basics of a Sustainable Model $415
  • #31: Machine Learning in Pharmacovigilance $415
  • #32: Experience the Technology Enabled Edition of the TransCelerate Common Protocol Template $415
  • #33: Quality Tolerance Limits/Issue Management: Taming the Beast of Clinical Development Risk $415
  • #34: Japan Regulatory Environment: Overview of the Organization, Processes, Systems, and Changes Affecting Pharmaceutical Development $415
  • #36: Value Pricing Bootcamp: A Crash Course in How to Use Real World Evidence to Better Measure Outcomes and Evaluate New Innovative Therapies $415
  • #37: Data Visualization in the Life Sciences $415
  • #38: From API via eCTD to ADR: Cross-Functional Data Sharing via Regulatory Information Excellence $415
  • #35: FDA Advisory Committee Purpose and Noninferiority Case Study: Rivaroxaban $415
  • #40: Smart, Innovative Risk-Based Auditing: Shifting the Paradigm $770
  • #42: Back to the Future: Combination Products in the 21st Century $770